Fda grants breakthrough device designation for haystack mrd circulating tumor dna test from quest diagnostics

Secaucus, n.j. , aug. 25, 2025 /prnewswire/ -- quest diagnostics (nyse: dgx), a leading provider of diagnostic information services, today announced that the u.s. food and drug administration (fda) has granted breakthrough device designation for the company's haystack mrd® test for identifying mrd-positive patients with stage ii colorectal cancer following curative-intent surgical treatment who may benefit from adjuvant therapy in accordance with therapeutic product labeling.
DNA Ratings Summary
DNA Quant Ranking